James S. Wilmott

机构：The University of Sydney, Melanoma Institute Australia · ORCID：0000-0002-6750-5244

发表论文 670 篇 · 总被引 63337 次 · h-index 87

代表论文

• Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma (2026 · npj Precision Oncology · 被引 6)
• GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma (2026 · Journal of Experimental & Clinical Cancer Research · 被引 3)
• OS2CR-Diff: A Self-Refining Diffusion Framework for CD8 Imputation from One-Step Inference to Conditional Representation (2025 · 被引 1)
• The immune landscape of primary melanoma: prognostic insights in the era of spatial biology and early immunotherapy (2026 · Journal of Translational Medicine)
• Immunospatial tumor microenvironment analysis identifies B cell aggregates associated with recurrence-free survival in primary melanoma (2026 · Cancer Immunology Immunotherapy)
• NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy. (2026 · Journal of Clinical Oncology)